Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.35 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.35 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22043740 | 0.77 | MAPT (0.40) | KDM4ETP53MAPT | |
| SCHEMBL22043754 | 0.77 | ALDH1A1 (0.43) | KDM4ETP53MAPTHDAC6FEN1 | |
| SCHEMBL22043741 | 0.77 | KDM4E (0.44) | KMOKDM4ETP53MAPTKCNQ3 | |
| SCHEMBL22043776 | 0.77 | MAPT (0.40) | KDM4ETP53MAPTCYP1A2NOTUM | |
| SCHEMBL22044253 | 0.77 | KDM4E (0.49) | KDM4ETP53MAPT | |
| SCHEMBL29993075 | 0.76 | AHR (0.55) | KMOEGLN2ABL1KCNH2AHR | |
| SCHEMBL12884908 | 0.74 | NPC1 (0.44) | KMOEGLN2CYP1A2ABL1NPC1 | |
| SCHEMBL22044443 | 0.74 | KIF11 (0.51) | — | |
| SCHEMBL35210214 | 0.74 | KIF11 (0.51) | — | |
| SCHEMBL12888477 | 0.73 | NPC1 (0.43) | KMOEGLN2CYP1A2ABL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3887359-B1 | NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING | UNIV COPENHAGEN (DK) | 2026-05-06 | — | — | EP | disclosed |
| US-20220119359-A1 | NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING | Københavns Universitet (DK) | 2022-04-21 | — | — | US | disclosed |
| US-20220119359-A1 | NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING | Københavns Universitet (DK) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119359-A1 | NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING | RTN3, RXFP3, TAAR5 | KMO 607/4885EGLN2 4308/4885KDM4E 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.